Meet Us – Centers of Cancer Nanotechnology Excellence (CCNEs)
Ian Baker, D. Phil., is the Sherman Fairchild Professor of Engineering at Dartmouth College and the Director of the Dartmouth Center for Cancer Nanotechnology Excellence. After completing a B.A. and D. Phil. in Metallurgy and Science of Materials at the University of Oxford, Dr. Baker joined the Faculty of the Thayer School of Engineering at Dartmouth College in 1982. He was Chair of Engineering Sciences (1996-2000); M.S./Ph.D. Program Director (2000-2005); Director, Center for Nanomaterials Research at Dartmouth (2002-2005); and has been the Senior Associate Dean for Academic Affairs since 2005. Dr. Baker was a CASE - NASA Co-operative Aerospace R&D Fellow at NASA-Lewis Research Center, Cleveland, OH, in summer 2005 and 2006, and Principal Research Metallurgist, Sherritt-Gordon Ltd., Fort Saskatchewan, Alberta in 1991.
Dr. Baker is a Chartered Engineer (U.K.) and a Fellow of ASM International and The Institute of Materials, Minerals and Mining (U.K.). He is the Editor-in-Chief of Materials Characterization, a Principal Editor of NanoLife, is on the editorial board of several journals, has published over 300 papers (200 in refereed journals) and has given over 300 presentations at conferences, universities and to industry. He has organized several conferences on snow firn, ice and intermetallic compounds and has supervised over 50 graduate students and ten postdoctoral fellows.
Dr. Baker's research interests include mechanical behavior, including wear and fracture of metals, compound semiconductors, intermetallic compounds and ice; processing and intermetallic compounds; recrystallization phenomena, particularly the effect of particles on recrystallization and processing by directional recrystallization; interdiffusion phenomena in metallic thin films and their influence on mechanical properties; applications of electron microscopy, X-ray diffraction and X-ray topography, particularly in-situ deformation experiments; the structure, chemistry and properties of firn and ice cores; production and properties of nanocrystalline, particularly magnetic, materials; and nanoparticles for biomedicalapplications.
Joseph DeSimone, Ph.D.
Chancellor's Eminent Professor of Chemistry
Director, Frank Hawkins Kenan Institute of Private Enterprise, Kenan-Flagler Business School
University of North Carolina at Chapel Hill
William R. Kenan Jr. Professor of Chemical Engineering
North Carolina State University
Joseph DeSimone, Ph.D., is the Chancellor's Eminent Professor of Chemistry and Director of the Frank Hawkins Kenan Institute of Private Enterprise, Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and William R. Kenan Jr. Professor of Chemical Engineering at North Carolina State University. He is also an Adjunct Member at Memorial Sloan-Kettering Cancer Center in New York. He has published over 270 scientific articles and has over 115 issued patents in his name with over 120 patents pending. In 2005 he was elected into the National Academy of Engineering and the American Academy of Arts and Sciences.
Dr. DeSimone has received 40 major awards and recognitions including the 2010 AAAS Mentor Award, the 2009 National Institutes of Health Director's Pioneer Award; the 2009 North Carolina Award; and the $500,000 Lemelson-MIT Prize for Invention and Innovation. In 2002, along with Richard Stack, M.D., a cardiologist at Duke and Robert Langer from MIT, Dr. DeSimone co-founded Bioabsorbable Vascular Solutions (BVS) to commercialize a fully bioabsorbable, drug-eluting stent. These stents are now being evaluated in a series of international clinical trials led by Abbott, enrolling over 1,000 patients, for the treatment of coronary artery disease. His group is now heavily focused on the development of a roll-to-roll particle fabrication technology known as PRINT (Particle Replication in Non-wetting Templates). Dr. DeSimone is exploiting the advantages of PRINT to generate "calibration quality" nano-tools to define the geometric (size, shape), surface (zeta potential, stealthing ligands) and deformability limitations associated with the delivery of drugs and vaccines using different dosage forms. Additionally, he recently launched Liquidia Technologies which now employs almost 50 people in the Research Triangle Park and has raised over $50 million in venture financing. Liquidia has converted PRINT into a GMP compliant process and has recently brought its first product, a seasonal influenza vaccine based on PRINT particles, into its first clinical trial.
Dr. DeSimone received his B.S. in Chemistry in 1986 from Ursinus College in Collegeville, PA and his Ph.D. in Chemistry in 1990 from Virginia Tech.
Sanjiv Sam Gambhir, M.D., Ph.D., is the Virginia & D.K. Ludwig Professor of Radiology, Bioengineering (by courtesy), and Materials Science & Engineering (by courtesy) at Stanford University. He is Director of the Molecular Imaging Program and head of Nuclear Medicine. He also heads up the new Canary Center at Stanford for Cancer Early Detection. He received his M.D./Ph.D. from the UCLA Medical Scientist Training Program. He directs over 200 scientists at Stanford, including 30 members of his own research laboratory. He has over 375 publications in the field and over 30 patents pending or granted. He is also co-editor of the leading textbook in Nuclear Medicine and a recent comprehensive book on Molecular Imaging.
An internationally recognized researcher in molecular imaging with over $75 million of National Institutes of Health funding as the Principal Investigator, Dr. Gambhir's lab has focused on interrogating fundamental molecular events in living subjects. He has developed and clinically translated several multimodality molecular imaging strategies including imaging of gene and cell therapies. He has also developed strategies for monitoring fundamental cellular events such as protein-protein interactions and protein phosphorylation in living subjects. Much of his work has bridged scientific disciplines including applied physics, chemistry, cell/molecular biology, life sciences, engineering, and biomathematics. He holds several FDA eIND/IND's and has clinically translated PET imaging agents.
Dr. Gambhir serves as an advisor to several major imaging and pharmaceutical companies and has also co-founded several imaging startups. He serves on numerous academic advisory boards for universities around the world and is also a member of the Board of Scientific Advisors of the National Cancer Institute. Among his many awards, he is the recipient of the Paul C. Aebersold Award for outstanding achievement in basic nuclear medicine science from the Society of Nuclear Medicine; 2009 Outstanding Researcher Award from the Radiological Society of Northern America; the Distinguished Clinical Scientist Award from the Doris Duke Charitable Foundation; the Holst Medal; the Tesla Medal; and the Hounsfield Medal from Imperial College, London. He was also elected as one of the youngest members of the Institute of Medicine (IOM) of the U.S. National Academies in 2008.
David G. Gorenstein, Ph.D., is Associate Dean for Research and Interim Chair of the Department of NanoMedicine and Biomedical Engineering at the University of Texas Health Sciences Center (UT HSC) at Houston. He is also Deputy Director of the Institute of Molecular Medicine and James T. Willerson Distinguished Chair and Professor, Centers for Proteomics and Systems Biology. He also serves as Director of the Gulf Coast Consortium in Magnetic Resonance, a shared facility that includes University of Texas Medical Branch, Rice, Baylor College of Medicine, University of Houston, UT HSC Houston, and University of Texas MD Anderson Cancer Center. He is Director of Translational Technologies for the UT HSC S/MD Anderson Cancer Center CTSA – the Center for Clinical and Translational Research.
Dr. Gorenstein has over 40 years experience in structural biology, drug design, nucleic acid and protein chemistry with over 260 publications. He has received a number of awards, including Guggenheim and Fulbright fellowships and election as Fellow to the American Association for the Advancement of Science (AAAS). Dr. Gorenstein holds over 36 patents (awarded and pending) on next-generation aptamer, bead-based combinatorial library selection technologies and is Founder of AM Biotechnologies, a spin-off company in Houston, which has licensed these technologies from his laboratory. Dr. Gorenstein is Principal Investigator (PI) on a National Institute of Child Health and Human Development (NICHD) Children's Study Center for Proteomics and Project Leader on both a National Heart, Lung and Blood Institute (NHLBI) Proteomics Center and a National Institute of Allergy and Infectious Diseases (NIAID) Clinical Proteomics Center in Infectious Diseases. He is also PI for the new Texas Center for Cancer Nanomedicine, one of the NCI Nanomedicine Centers.
Dr. Gorenstein received his S.B. degree at the Massachusetts Institute of Technology and his Ph.D. at Harvard University, in Chemistry.
Mauro Ferrari, Ph.D., is the President and CEO of The Methodist Hospital Research Institute (TMHRI). In addition, he holds the Ernest Cockrell Jr. Distinguished Endowed Chair at TMHRI. Dr. Ferrari is also Professor of Internal Medicine at the Weill Cornell Medical College and Adjunct Professor of Bioengineering at Rice University. Dr. Ferrari is the President of the Alliance for NanoHealth, a consortium organizations formed by eight universities in Houston to promote interdisciplinary and translational research of medical nanotechnology.
Dr. Mauro Ferrari is a founder of biomedical nano/micro-technology, especially in its applications to drug delivery, cell transplantation, implantable bioreactors, and other innovative therapeutic modalities. In these fields, he has published more than 200 peer-reviewed journal articles and six books. He is the inventor of more than 30 issued patents, with about 30 more pending in the United States and internationally. His contributions have been recognized by a variety of accolades, including: the Presidential Young Investigator Award of the National Science Foundation; the Shannon Director's Award of the National Institutes of Health (NIH); the Wallace H. Coulter Award for Biomedical Innovation and Entrepreneurship; and the Italiani nel Mondo Award from the Italian Ministry of Foreign Affairs. His career research and development portfolio totals over $50 million, including support from the National Cancer Institute (NCI), NIH, Department of Defense, National Aeronautics and Space Administration, National Science Foundation, Defense Advanced Research Projects Agency, Department of Energy, the State of Texas, the State of Ohio, The Ohio State University, and several private enterprises. Dr. Ferrari also served as Special Expert on Nanotechnology at the NCI in 2003-2005, providing leadership into the formulation, refinement, and approval of the NCI Alliance for Nanotechnology in Cancer, currently the world's largest program in medical nanotechnology.
Dr. Ferrari received his Ph.D., in Mechanical Engineering at the University of California, Berkeley.
S. Nahum Goldberg M.D., FSIR, is an Interventional Oncologist at Beth Israel Deaconess Medical Center (BIDMC) and Division Head of Image-guided Therapy at Hadassah Hebrew University Medical Center. He is also a Full Professor at Harvard Medical School, Boston, Massachusetts and Hebrew University, Jerusalem, Israel. Following 12 years of experience working with radiofrequency (RF) tumor ablation and imaging studies, Dr. Goldberg recently completed a National Institutes of Health project on "Enhanced RF Tumor Ablation with Liposomal Chemotherapy," studying modulation of liposomal doxorubicin nanocarrier components to increase tumor toxicity in the presence of RF energy. He is also Principal Investigator (PI) of the project, "Combined Cancer Therapy with RF Ablation and Drug-Loaded Nanopreparations." Dr. Goldberg also has considerable experience with oncologic clinical trials and interventional oncologic techniques. He was named Commission on Collegiate Nursing Education clinical PI where he is poised to rapidly translate gains into clinical practice, via the "Quick Trials" pathway of the Dana Farber/Harvard Cancer Center in which he participates as an active investigator in GI and GU and is governing member of the Renal Tumor SPORE.
As the Director of the Minimally Invasive Tumor Therapies Laboratory at BIDMC and Director of the Applied Radiology Laboratory at Hadassah Hebrew University, Dr. Goldberg has authored more than 140 original scientific manuscripts, 25 book chapters and reviews, and eight patents. The majority of his research concerns developing and advancing image guided minimally-invasive techniques such as radiofrequency ablation for the treatment of cancer. This work is accomplished in the laboratory through development and optimization of new devices, by elucidation of the principles governing thermal methods for tumor destruction, by establishing how to best combine tumor ablation and chemotherapy most notably with nanotechnology, and by rapidly translating these advances to the clinic through rigorously controlled collaborative studies. In addition, Dr. Goldberg worked on improving methods of gene therapy and stem cell delivery to treat cancer and genetic diseases as a Fulbright Scholar at Hadassah Hebrew University. Besides being named a Fellow of the Society of Interventional Radiology, he has served on multiple national and international committees advancing this discipline, most recently serving as the Section Editor for a new Interventional Oncology series in Radiology.
Dr. Goldberg graduated from Yeshiva University, New York, NY and obtained his M.D., at Yale School of Medicine.
James R. Heath, Ph.D.
Elizabeth W. Gilloon Professor and Professor of Chemistry, California Institute of Technology; Professor of Molecular & Medical Pharmacology, University of California, Los Angeles
James R. Heath, Ph.D., is the Elizabeth W. Gilloon Professor and Professor of Chemistry at Caltech, and Professor of Molecular & Medical Pharmacology at the University of California, Los Angeles (UCLA), and Director of the National Cancer Institute's NSB Cancer Center.
Dr. Heath was a Miller Fellow at University of California Berkeley from 1988-91, and on the Technical Staff at IBM Watson Labs from 1991-93. In 1994, he joined the faculty at UCLA. He founded the California NanoSystems Institute in 2000 and served as its Director until moving to Caltech. Dr. Heath has investigated quantum phase transitions, and he has developed architectures, devices, and circuits for molecular electronics. His group has recently been applying their advances on nanoelectronics circuitry toward addressing problems in cancer.
Dr. Heath has received a number of awards, including a Public Service Commendation from Governor Grey Davis, the Sackler Prize, the Spiers Medal, the Feynman Prize, the Jules Springer Prize, and the Arthur K. Doolittle Award. He has founded or co-founded several companies, including NanoSys, MTI, MoB, and Homestead Clinical Corporation, and has served on the board of a number of organizations, including the Board of Scientific Advisors of the National Cancer Institute.
Dr. Heath received a B.Sc. degree from Baylor College and his Ph.D., in Chemistry from Rice University, where he was the principal student involved in the Nobel Prize–winning discovery of C60 and the fullerenes.
Leroy Hood, M.D., Ph.D., is an Affiliate Professor of Immunology at the University of Washington and Founder and Chairman of the cross-disciplinary Department of Molecular Biotechnology. Dr. Hood co-founded the Institute for Systems Biology in Seattle, Washington to pioneer systems approaches to biology and medicine.
Dr. Hood's research has focused on the study of molecular immunology, biotechnology, and genomics. His professional career began at Caltech where he and his colleagues pioneered four instruments – the DNA gene sequencer and synthesizer, and the protein synthesizer and sequence – which comprise the technological foundation for contemporary molecular biology. In particular, the DNA sequencer has revolutionized genomics by allowing the rapid automated sequencing of DNA, which played a crucial role in contributing to the successful mapping of the human genome during the 1990s.
Most recently, Dr. Hood's lifelong contributions to biotechnology have earned him the prestigious 2004 Association for Molecular Pathology (AMP) Award for Excellence in Molecular Diagnostics and the 2003 Lemelson–MIT Prize for Innovation and Invention. He was also awarded the 2002 Kyoto Prize in Advanced Technology and the 1987 Lasker Prize for his studies on the mechanism of immune diversity. He has published more than 600 peer-reviewed papers, received 14 patents, and has co-authored textbooks in biochemistry, immunology, molecular biology, and genetics, and is a member of the National Academy of Sciences, the American Philosophical Society, the American Association of Arts and Sciences, and the Institute of Medicine. Dr. Hood has also played a role in founding numerous biotechnology companies, including Amgen, Applied Biosystems, Systemix, Darwin, and Rosetta.
Dr. Hood received his M.D. from Johns Hopkins School of Medicine in 1964 and his Ph.D., in Biochemistry in 1968 from the California Institute of Technology.
Robert Langer, Sc.D., is the David H. Koch Institute Professor at Massachusetts Institute of Technology (MIT). He has written approximately 1,050 articles. He is the most cited engineer in history. Dr. Langer has received over 170 major awards including the 2006 United States National Medal of Science; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers; and the 2008 Millennium Prize, the world's largest technology prize. He is also the only engineer to receive the Gairdner Foundation International Award; 72 recipients of this award have subsequently received a Nobel Prize. Among numerous other awards Dr. Langer has received are the Dickson Prize for Science (2002); Heinz Award for Technology; Economy and Employment (2003); the Harvey Prize (2003); the John Fritz Award (2003) (given previously to inventors such as Thomas Edison and Orville Wright); the General Motors Kettering Prize for Cancer Research (2004); the Dan David Prize in Materials Science (2005); the Albany Medical Center Prize in Medicine and Biomedical Research (2005), the largest prize in the United States for medical research; induction into the National Inventors Hall of Fame (2006); the Max Planck Research Award (2008); the Prince of Asturias Award for Technical and Scientific Research (2008); and 15 honorary doctorates, including ones from Harvard and Yale. In 1998, he received the Lemelson-MIT prize, the world's largest prize for invention for being "one of history's most prolific inventors in medicine." In 1989 Dr. Langer was elected to the Institute of Medicine of the National Academy of Sciences, and in 1992 he was elected to both the National Academy of Engineering and to the National Academy of Sciences. He is one of very few people ever elected to all three United States National Academies and the youngest in history (at age 43) to ever receive this distinction.
Dr. Langer received his Bachelor's Degree from Cornell University and his Sc.D. from MIT in 1974, both in Chemical Engineering.
Gabriel Lopez-Berestein, M.D., is a Professor of Medicine, Cancer Biology and Experimental Therapeutics at the University of Texas Anderson Cancer Center. He is also a Professor of Nanomedicine and Bioengineering at the University of Texas Health Sciences Center at Houston.
Since early in his career, Dr. Lopez-Berestein has studied the role of the monocyte lineage and cell signaling in cancer. He has developed a number of nanoparticle-based therapeutics in cancer and infectious diseases and has a special interest in RNAi and ncRNAs as well as the theranostics of cancer.
Dr. Lopez-Berestein received his M.D. from the University of Navarra, Spain.
Chad A. Mirkin, Ph.D.
Director of the International Institute for Nanotechnology, George B. Rathmann Professor of Chemistry, Professor of Chemical and Biological Engineering, Professor of Biomedical Engineering, Professor of Materials Science & Engineering, and Professor of Medicine
Chad A. Mirkin, Ph.D., is the Director of the International Institute for Nanotechnology, the George B. Rathmann Professor of Chemistry, Professor of Chemical and Biological Engineering, Professor of Biomedical Engineering, Professor of Materials Science & Engineering, and Professor of Medicine at Northwestern University.
Dr. Mirkin is a chemist and a world renowned nanoscience expert, known for his development of nanoparticle-based biodetection schemes, the invention of Dip-Pen Nanolithography, and contributions to the invention and development of gene regulation strategies based upon polyvalent nucleic acid nanostructure conjugates. He is the author of over 430 manuscripts and over 370 patents and applications, and the founder of three companies, Nanosphere, NanoInk, and AuraSense which are commercializing nanotechnology applications in the life science and semiconductor industries.
Dr. Mirkin has been recognized for his accomplishments with over 60 national and international awards. He is a Member of the President's Council of Advisors on Science and Technology (PCAST, Obama Administration), Member of the Institute of Medicine, the National Academy of Sciences, and the National Academy of Engineering, and is a Fellow of the American Association for the Advancement of Science. Dr. Mirkin has served on the Editorial Advisory Boards of over twenty scholarly journals. He is the founding editor of the journal Small, one of the premier international nanotechnology journals, and he has co-edited two bestselling books on nanobiotechnology.
Dr. Mirkin holds a B.S. degree from Dickinson College and a Ph.D. degree in Chemistry from the Pennsylvania State University.
Keith D. Paulsen, Ph.D., is the Robert A. Pritzker Chair in Biomedical Engineering at the Thayer School of Engineering at Dartmouth, Professor of Radiology at Dartmouth Medical School, Director of the Advanced Imaging Center at Dartmouth Hitchcock Medical Center and Co-Director of the Cancer Imaging and Radiobiology Research Program at the Norris Cotton Cancer Center. He is also the Deputy Director for the Dartmouth Center of Nanotechnology Excellence. Dr. Paulsen specializes in cancer imaging and has maintained an active research program with funding from the National Institutes of Health (NIH) for more than twenty years that is currently focused on the development and evaluation of imaging methods for diagnostic and therapeutic clinical decision-making in the identification and management of cancers, primarily of the breast and brain. He has published over 280 articles in the peer-reviewed scientific and medical literature and has contributed more than 350 papers, presentations, and abstracts to scientific meetings and conferences. Dr. Paulsen served as a chartered member of the Radiation Research Study Section from 1996-2000 and the Biomedical Imaging Technology Study Section from 2002-2006 within the Center for Scientific Review and continues to be active in NIH peer review.
Dr. Paulsen received his B.Sc., M.S., and Ph.D. in Engineering Sciences from Dartmouth College.
Michael Phelps, Ph.D.
Norton Simon Professor, Chair of the Basic and Clinical Sciences Department of Molecular & Medical Pharmacology, Director of the Translational Sciences Institute for Molecular Medicine, and Director of the Crump Institute for Molecular Imaging
University of California Los Angeles
Michael Phelps, Ph.D., is the Norton Simon Professor, Chair of the Basic and Clinical Sciences Department of Molecular & Medical Pharmacology, Director of the Translational Sciences Institute for Molecular Medicine (IMED) and Director, Crump Institute for Molecular Imaging at University of California Los Angeles (UCLA). Dr. Phelps is the co-Principal Investigator with Dr. James Heath and Dr. Leroy Hood of the NCI Nanosystems Biology Cancer Center.
Dr. Phelps has published 720 peer-reviewed articles, books and book chapters, and was elected to the Institute of Medicine in 1985 and to the National Academy of Sciences in 1999. Among his awards are: George von Hevesy Prize; S. Weir Mitchell Award, Academy of Neurology; Department of Energy Ernest O. Lawrence Award; Rosenthal Foundation Award, American College of Physicians; Enrico Fermi Presidential Award, President Clinton; Kettering Prize, General Motors Cancer Research Foundation; and gave the Keynote Address, 2007 Nobel Symposium, Stockholm. Dr. Phelps is Chairman of the Board, Norton Simon Foundation; Board Member, Norton Simon Art Foundation; and was one of the three founders and member of the Board of Directors, CTI, Molecular Imaging that was acquired by Siemens in 2005.
Dr. Phelps earned B.S. degrees in Chemistry and Mathematics at Western Washington State University, and a Ph.D. in Chemistry from Washington University. He was on the faculty of the Schools of Medicine and Engineering, Washington University and then the UCLA School of Medicine. Dr. Phelps, along with his post doc at the time, Dr. Edward Hoffman, is the inventor of the Positron Emission Tomography (PET) scanner.
Martin Pomper, M.D., Ph.D., is the co-director of the Johns Hopkins Center of Cancer Nanotechnology Excellence. Dr. Pomper is professor of Radiology with other joint appointments at Johns Hopkins University. He is board-certified in diagnostic radiology and nuclear medicine, he has served on the Radiology faculty at Johns Hopkins since 1996. He currently directs the Johns Hopkins Small Animal Imaging Resource and is associate director of the In Vivo Cellular and Molecular Imaging Center, both funded by the National Cancer Institute to support molecular imaging research. In addition, he directs the Johns Hopkins Center for Translational Molecular Imaging and the Positron Emission Tomography Center.
Dr. Pomper's research interests include the development of new radiopharmaceuticals, optical probes, and techniques for molecular imaging of cancer and central nervous system disease. His research group consists of chemists, physicists, molecular biologists, and clinicians working together toward clinical molecular imaging. He is editor-in-chief of Molecular Imaging and a past president of the Society of Nuclear Medicine's Molecular Imaging Center of Excellence. He holds numerous patents related to medical imaging, many of which have been licensed, as well as several imaging agents in clinical trials.
Dr. Pomper received his bachelor's and doctorate in Organic Chemistry and his medical degree from the University of Illinois at Urbana-Champaign.
Steven T. Rosen, M.D., FACP
Genevieve Teuton Professor of Medicine, Feinberg School of Medicine, Northwestern University; Director, Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Steven Rosen, M.D., FACP, is Genevieve Teuton Professor of Medicine, at the Feinberg School of Medicine, Northwestern University and Director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Director of Cancer Programs at Northwestern Memorial Hospital. Dr. Rosen's laboratory research focuses on experimental therapeutics and hematologic malignancies. Dr. Rosen has received numerous grant awards and contracts and has published more than 250 scientific papers. As Director of the Cancer Center, Dr. Rosen has successfully competed for the National Cancer Institute (NCI) Cancer Center Support Grant, NCI grants for his laboratory research, an NCI RAID Contract grant for the development of a novel purine analog, and grants from the Leukemia and Lymphoma Society of America and the American Cancer Society. Dr. Rosen is the co-Principal Investigator of Northwestern's NCI Center of Cancer Nanotechnology Excellence Grant.
Dr. Rosen serves on several editorial boards and is editor of Cancer Treatment & Research. He is a member of all major national associations that focus on oncology and has held leadership positions in the Eastern Cooperative Oncology Group, the American Association of Cancer Institutes, and the National Comprehensive Cancer Network. He serves on the advisory boards of several NCI-designated Cancer Centers, the Leukemia and Lymphoma Society of America, the Multiple Myeloma Research Foundation, the Lymphoma Research Foundation and the Wendy Will Cancer Research Foundation. He has also served as an advisor to Great Britain's Cancer Research Campaign. Dr. Rosen was the recipient of Northwestern University Medical School's Alumni Achievement Award (1994), the Martin Luther King Humanitarian Award from Northwestern Memorial Hospital (1995), the Marv Samuel Award from the Chicago Baseball Cancer Charities (1996) and recognition from the Women's Board of Northwestern Memorial Hospital for Compassionate Care (1996). He is acknowledged in Best Doctors in America and Best Doctors in Chicago.
Dr. Rosen graduated with distinction from Northwestern University Medical School's Six-Year Honors Program in 1976. He completed his residency in Internal Medicine at Northwestern and a fellowship in Medical Oncology at the National Cancer Institute.
Peter C. Searson, Ph.D., co-Directs the Johns Hopkins Center of Cancer Nanotechnology Excellence. He is the Joseph R. and Lynn C. Reynolds Professor of Materials Science and Engineering at the Whiting School of Engineering, Johns Hopkins University. Dr. Searson's research interests include the synthesis and characterization of nanostructured materials, electrodeposition and patterning, applications for nanotechnology in biology and medicine, surface and molecular engineering, and semiconductor quantum dots. For his distinguished contributions to the field of surface chemistry and nanoscience, Dr. Searson was named a fellow of the American Association for the Advancement of Science in 2009.
Dr. Searson led the launch and serves as director of the Johns Hopkins Institute for NanoBioTechnology, which was established in 2006 as an interdivisional center that brings together researchers from medicine, engineering, the sciences, and public health to create new knowledge and develop new technologies to revolutionize health care and medicine. He worked as a senior scientist at the Stanford Research Institute. He has been a member of the Johns Hopkins faculty since 1990 with joint appointments in the departments of Chemical and Bimolecular Engineering, Physics and Astronomy, and Oncology and has been awarded the IBM distinguished faculty award two years in a row. He served as a visiting professor at Nanjing University in China and also at École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland. He is the former Associate Director of the Johns Hopkins Materials Research Science and Engineering Center.
Dr. Searson earned his Ph.D. in Materials Science and Engineering at the University of Manchester, Institute of Science and Technology (UK) and was a postdoctoral associate in the Department of Materials Science & Engineering at Massachusetts Institute of Technology.
Anil K. Sood, M.D., is professor in the Departments of Gynecologic Oncology and Cancer Biology and co-Director of the Center for RNA Interference and Non-Coding RNA at the MD Anderson Cancer Center. He is also co-Director of the multidisciplinary Blanton-Davis Ovarian Cancer Research Program and Vice Chair for Translational Research in the Department of Gynecologic Oncology.
Dr. Sood's research is focused in three main areas: Development of new strategies for in vivo siRNA delivery; development of novel anti-vascular therapeutic approaches; and effect of neuroendocrine stress hormones on ovarian cancer growth and progression. Dr. Sood has received major recognition for his research accomplishments including the Hunter Award from the American Gynecological and Obstetrical Society, and the Margaret Greenfield/Carmel Cohen Excellence in Ovarian Cancer Research Prize. He has published numerous peer-reviewed articles and has authored and co-authored several book chapters, and he serves on the editorial board for several journals and as a reviewer for many others. He was recently elected to the prestigious American Society for Clinical Investigation, an honor society for physician-scientists. Dr. Sood is actively involved in teaching graduate students and clinical fellows. He is a member of The University of Texas Graduate School of Biomedical Sciences and teaches classes related to cancer cell signaling pathways.
Dr. Sood received his M.D. from the University of North Carolina, Chapel Hill.
Joel Tepper, M.D., is co-Director of the Carolina Center for Cancer Nanotechnology Excellence at the University of North Carolina (UNC), Chapel Hill. He is also Director of the UNC Specialized Program of Research Excellence (SPORE) program in gastrointestinal (GI) disease. He has been a Professor at UNC Chapel Hill for over 23 years, and was Chair of the Department of Radiation Oncology for almost 20 years, before stepping down to pursue his research efforts. Dr. Tepper is primarily involved in translational research in gastrointestinal tumors, and has been heavily involved in the translation of new technologies into clinical application.
Dr. Tepper has served the National Cancer Institute (NCI) in multiple capacities including being a founding member of the Clinical Trials and Translational Research Advisory Committee to the Director of the NCI and being Co-Chair of the NCI GI Steering Committee for the past five years, as well as Chair of the Steering Committee Chairs. He was Vice-Chair of the GI Committee of the Cancer and Leukemia Group B (CALGB) for 14 years. He has been President and Chairman of the Board of the American Society for Radiation Oncology (ASTRO), as well as a member of the Board of Directors of the American Society of Clinical Oncology (ASCO). Dr. Tepper is editor of two books and is the founding editor of Seminars in Radiation Oncology.
Dr. Tepper received his undergraduate degree in Electrical Engineering from the Massachusetts Institute of Technology, his M.D. from Washington University (St. Louis), and he trained at the Massachusetts General Hospital (MGH) in Radiation Oncology. He has also been a Senior Investigator at the National Cancer Institute and a faculty member at MGH and Harvard Medical School.
Vladimir P. Torchilin, Ph.D., D.Sc., is a Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, Massachusetts. In 1991 Dr. Torchilin joined Massachusetts General Hospital and Harvard Medical School as the Head of their Chemistry Program, Center for Imaging and Pharmaceutical Research, and Associate Professor of Radiology. Dr. Torchilin is the former chair of Northeastern University's Department of Pharmaceutical Sciences. His research interests have focused on biomedical polymers, drug delivery and targeting, pharmaceutical nanocarriers for diagnostic and therapeutic agents, and experimental cancer immunology.
He has published more than 300 original papers, more than 100 reviews and book chapters, wrote and edited 10 books, including Immobilized Enzymes in Medicine; The Handbook on Targeted Delivery of Imaging Agents; Liposomes: A Practical Approach; Nanoparticulates as Pharmaceutical Carriers; Multifunctional Pharmaceutical Nanocarriers; Biomedical Aspects of Drug Targeting; Delivery of Protein and Peptide Drugs in Cancer; and holds more than 40 patents. He is Editor-in-Chief of Current Drug Discovery Technologies, co-Editor-in-Chief of Drug Delivery and on the Editorial Boards of many leading journals in the field, including Journal of Controlled Release (Review Editor); Bioconjugate Chemistry; Advanced Drug Delivery Reviews; European Journal of Pharmaceutics and Biopharmaceutics; Journal of Drug Targeting; Molecular Pharmaceutics; Journal of Biomedical Nanotechnology; and others.
Among his many awards, Dr. Torchilin was the recipient of the 1982 Lenin Prize in Science and Technology (the highest scientific award in the former Union of Soviet Socialist Republics). He was elected as a Member of European Academy of Sciences. He is also a Fellow of the American Institute of Medical and Biological Engineering and the American Association of Pharmaceutical Scientists (AAPS), and received the 2005 Research Achievements in Pharmaceutics and Drug Delivery Award from the AAPS; 2007 Research Achievements Award from the Pharmaceutical Sciences World Congress; 2009 AAPS Journal Award; 2009 International Journal of Nanomedicine Distinguished Scientist Award; and 2010 Controlled Release Society Founders Award. In 2005-2006, he served as a President of the Controlled Release Society.
Dr. Torchilin graduated from the Moscow University with a M.S. in Chemistry, and also went on to earn a Ph.D. and D.Sc. in Polymer Chemistry, Chemical Kinetics and Catalysis, and Chemistry of Physiologically Active Compounds in 1971 and 1980, respectively.
Dr. Shan X. Wang, Ph.D., currently serves as the director of the Stanford Center for Magnetic Nanotechnology and a Professor of Materials Science & Engineering and Electrical Engineering at Stanford University, and by courtesy, a Professor of Radiology at Stanford Medical School. He is a co-Principal Investigator of the Stanford-led Center for Cancer Nanotechnology Excellence and Translation (CCNE-T), and the Principal Investigator of the Rapid and Accurate Proteomic Index Dosimetry (RAPID) Consortium including Stanford University and Lawrence Berkeley National Lab. He is also with the Geballe Laboratory for Advanced Materials, and is affiliated with Stanford Bio-X Program and Cardiovascular Institute.
Dr. Wang's research interests lie in magnetic nanotechnologies and information storage and include magnetic biochips, in vitro diagnostics, magnetic nanoparticles, nano-patterning, spin electronic materials and sensors, magnetic inductive heads, as well as magnetic integrated inductors and transformers. He has published over 180 papers, and holds 27 patents (issued and pending) on these subjects. Dr. Wang contributed to two books and three book chapters on magnetic biochip, nanoparticles, information storage, and embedded inductors, respectively, and has given more than 70 invited presentations in major scientific conferences and meetings. His work has received media coverage from ABC TV, The Economist, San Jose Mercury News, Technology Review, EE Times, ScienceWatch, People's Daily, and other major media outlets.
Dr. Wang was an inaugural Frederick Terman Faculty Fellow at Stanford University (1994-1997), an IEEE Magnetics Society Distinguished Lecturer (2001-2002), and was elected an IEEE Fellow (2009). He also received the Gates Foundation Grand Challenge Explorations Award (2010), the Obducat Prize (2007-2008), a National Academies Keck Futures Initiative Award (2006), an IBM Partnership Award (1999), and was selected to the CUSPEA program organized by Nobel Laureate T. D. Lee in 1986. His students have won the BMEidea Competition 1st Prize and IEEE President's Change the World Competition 1st Prize (2009).
Dr. Wang received a B.S. degree in Physics from the University of Science and Technology of China in 1986, M.S. in Physics from Iowa State University in 1988, and Ph.D. in Electrical and Computer Engineering from the Carnegie Mellon University in 1993.
Ralph Weissleder, M.D., Ph.D.
Professor, Harvard Medical School; Director, Massachusetts General Hospital Center for Systems Biology; Attending Clinician, Department of Radiology, Massachusetts General Hospital
Ralph Weissleder, M.D., Ph.D., is a Professor at Harvard Medical School, Director of the Massachusetts General Hospital (MGH) Center for Systems Biology, and an Attending Clinician in the Department of Radiology at MGH. Dr. Weissleder's research interests include the development of novel molecular imaging techniques, tools for detection of early disease detection, development of nanomaterials for sensing and systems analysis. His research has been translational and several of his developments have led to advanced clinical trials with anticipated major impacts when these methods become routinely available. Dr. Weissleder is currently the Principal Investigator of several RO1 National Institutes of Health grants, a P50 Center grant, a U24 grant, and a UO1 consortium focusing on nanotechnology. He has published over 600 original publications in peer-reviewed journals and has authored several textbooks. He is a founding member of the Society for Molecular Imaging Research and served as its President in 2002. His work has been honored with numerous awards including the J. Taylor International Prize in Medicine, the Millenium Pharmaceuticals Innovator Award, the AUR Memorial Award, the American Roentgen Ray Society (ARRS) President's Award, The Society for Molecular Imaging Lifetime Achievement Award, the Academy of Molecular Imaging 2006 Distinguished Basic Scientist Award, and the 2008 Radiological Society of North America Outstanding Researcher Award. In 2009, he was elected member of the U.S. National Academies Institute of Medicine.
Dr. Weissleder received his M.D. and Ph.D. from the University of Heidelberg.